One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin.

Daniel B Brown  
*Thomas Jefferson University, Daniel.Brown@jefferson.edu*

Carin F Gonsalves  
*Thomas Jefferson University, Carin.Gonsalves@jefferson.edu*

Charles J Yeo  
*Thomas Jefferson University, Charles.Yeo@jefferson.edu*

Agnes K Witkiewicz  
*Thomas Jefferson University, Agnieszka.Witkiewicz@jefferson.edu*

Brian I Carr  
*Thomas Jefferson University, Brian.Carr@jefferson.edu*

Let us know how access to this document benefits you

Follow this and additional works at: [http://jdc.jefferson.edu/radiologyfp](http://jdc.jefferson.edu/radiologyfp)

Part of the [Oncology Commons](http://jdc.jefferson.edu/oencologyfp), [Pathology Commons](http://jdc.jefferson.edu/pathologyfp), [Radiology Commons](http://jdc.jefferson.edu/radiologyfp), and the [Surgery Commons](http://jdc.jefferson.edu/surgeryfp)

**Recommended Citation**

Brown, Daniel B; Gonsalves, Carin F; Yeo, Charles J; Witkiewicz, Agnes K; and Carr, Brian I, "One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin." (2010). *Department of Radiology Faculty Papers*. Paper 23.  
[http://jdc.jefferson.edu/radiologyfp/23](http://jdc.jefferson.edu/radiologyfp/23)
Abstract. While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.

Introduction
Pancreatic adenocarcinoma is the 4th most common cause of cancer death in the United States with 37,700 new diagnoses and 34,300 deaths projected for 2008 (1). Outcomes following margin negative resection have improved over the last decade with 5-year survival ranging from 7-24% (2). However, metastatic disease to the liver is a premortal condition. Median survival with metastatic pancreatic cancer is 4-6 months. Even with newer agents, such as gemcitabine and erlotinib, survival for metastatic cancer from the pancreas has not appreciably improved over the last decade. Pancreatic metastases typically spread hematologically or via regional lymphatics to the liver and lung. Transarterial therapies such as chemoembolization, embolization and radioembolization with 90Y have demonstrated substantial improvement in survival and symptoms when used to treat unresectable hepatic disease either originating in the liver or metastasizing to the liver (3). However, transarterial therapy of liver dominant metastatic pancreatic carcinoma has not been extensively evaluated. We report a complete radiographic response in a patient with liver isolated metastases from pancreatic carcinoma one year following initiation of therapy with a review of the relevant literature.

Case report
This type of review does not require approval by our institution's IRB. This 56-year old male was diagnosed with a 4-cm mass in the pancreatic tail. The initial metastatic workup included MR, CT, and PET scans. This revealed no evidence of metastatic disease (Fig. 1A). The tumor focally invaded the splenic hilum and the splenic vein was thrombosed. His pre-operative CA 19-9 was 209 U/ml (normal <36 U/ml). The patient underwent a distal pancreatectomy and en bloc splenectomy in July 2008 and made an uncomplicated recovery. Pathology revealed a grade III poorly differentiated 4.0x3.0-cm ductal adenocarcinoma with signet ring features (Fig. 1B). The final report noted that the tumor contained synchronous pancreatic intraepithelial neoplasia with the highest grade being PanIN 2. Eight lymph nodes were resected and all were free of disease. The margins of the surgical specimen were uninvolved by tumor. The patient recovered uneventfully and was discharged home.

Follow-up CT in September 2008 demonstrated a 2.4x2.8-cm mass in the anterior segment of the right hepatic lobe (Fig. 1C). Sonographically guided fine needle aspiration confirmed the diagnosis of metastatic adenocarcinoma. He was referred for chemoembolization. Thermal ablation for this mass was considered but not performed given the concern that other hepatic micrometastases were likely present. In September 2008 after obtaining informed consent, the patient
underwent chemoembolization with gemcitabine 1,000 mg/m² and cisplatin 100 mg/m². The patient was pre-medicated with anti-emetics, steroids, diuretics, and sodium thiosulfate. The right hepatic artery was selected with a micro-catheter. Following infusion of the chemotherapeutic agents, embolization to near stasis was performed with a gelfoam slurry. He was hydrated overnight (including continued thiosulfate) and discharged the following morning.

At repeat imaging, the mass was similar in size albeit less well-defined. The patient underwent similar weight based chemoembolization again in November, 2008 after which a partial response using Response Evaluation Criteria in Solid Tumors (RECIST) criteria was identified. The patient underwent 2 more similar sessions in January and March, 2009. Follow-up MRI in June, 2009 did not demonstrate any evidence of malignancy (Fig. 1D). Given that the patient’s primary tumor was metabolically active prior to resection, CT/PET was repeated. No hypermetabolic foci were present (Fig. 1E).

**Discussion**

Shibata *et al* reviewed outcomes of patients with recurrent disease following attempted curative resection of pancreatic carcinoma (4). Multivariate analysis found that patients with poorly differentiated tumors had a significantly greater risk of developing liver metastases ($p=0.014$, Odds Ratio of 7.432). Patients with hepatic metastases had a mean survival of 13 months and a 0% 5-year survival. Gemcitabine is the cornerstone of therapy for metastatic pancreatic carcinoma.
based on a previous randomized trial where patients survived a median of 5.65 months with 18% surviving one year (5). Since that trial, a number of studies have been performed in an attempt to find a combination with gemcitabine to further extend survival without success. Most recently, 832 patients enrolled in a phase III trial studying gemcitabine 1,000 mg/m² given over 30 min versus gemcitabine 1,500 mg/m² given over 150 min versus combination gemcitabine 1,000 mg/m²/100 min and oxaliplatin 100 mg/m² on consecutive days (1). Simple 30-min infusions of gemcitabine were superior to either higher doses or the addition of a second agent. The authors noted that other phase III trials evaluating the combination gemcitabine with biologic agents such as bevacizumab or cetuximab have similarly had disappointing results.

Cisplatin has been used as a combination agent with gemcitabine in a phase II trial for metastatic pancreatic carcinoma (6). Patients in this study received gemcitabine 1,000 mg/m² over 30 min on days 1, 8, and 15 of each cycle and cisplatin 75 mg/m² following the first drug on day 1. Although this treatment regimen requires validation by performance of a phase III study, median survival in this 52 patient group was 11.8 months and 50% remained alive at 12 months. Based on this study, exploration of gemcitabine and cisplatin infusion/embolization for patients with liver dominant pancreatic carcinoma could have merit to maximize drug delivery. Investigation is particularly of value in light of the abysmal survival in this patient group with standard systemic therapy.

There are few reports of arterial chemoinfusion or embolization to treat hepatic metastases from pancreatic carcinoma. Most have involved infusions lasting several days. Furuse et al performed 5-day infusions of 5-fluorouracil (5-FU) 500 mg/m²/day every 4 weeks in 13 patients (7). One patient (8%) demonstrated a partial response. The prolonged infusions of 5-FU resulted in hepatic arterial occlusion in 3 patients. While no grade III or IV toxicities occurred, median survival was only 15.9 weeks. Ishii et al investigated the combination of weekly 5-FU 1,000 mg/m² over 5 h plus 50 Gy external beam radiation to the unresected pancreatic malignancy (2 Gy in 25 fractions) (8). Thirteen patients received a median of 13 cycles of chemotherapy. Seven (41%) of the patients demonstrated a partial response. Four patients developed duodenal ulcers and 2 patients developed grade III or greater toxicity. The median overall survival was 4.5 months with a 1-year survival of 11.8%. The final study in the English language reported on attempted neoadjuvant arterial infusion with intra-arterial infusion of cisplatin at 10 mg/m²/day and 5-FU at 500 mg/m²/day (9). After 14 days of infusion, the patient developed a vasculopathy preventing further intra-arterial therapy. One potential advantage in the technique described in our patient is the relatively short infusion times. With aggressive hydration and treatment with antiemetics and thiosulfate, he was able to be discharged the day following each procedure. Over 4 intra-arterial infusions, our patient had no reportable toxicity using the Common Terminology Criteria for Adverse Events, version 3 (CTCAE v3).

While the outcome in this patient is promising, enthusiasm for this outcome needs to be tempered by the limited experience in other patients. However, the response to therapy along with the absence of toxicity suggests that there may be a role for catheter directed intra-arterial therapy for patients with liver dominant metastases from pancreatic carcinoma. Given the poor outcomes with standard therapies in this patient group, further investigation of catheter directed therapy in appropriate patients should be performed.

References